Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E. Gómez-Miragaya J, et al. Among authors: urruticoechea a. Stem Cell Reports. 2017 May 9;8(5):1392-1407. doi: 10.1016/j.stemcr.2017.03.026. Epub 2017 Apr 27. Stem Cell Reports. 2017. PMID: 28457887 Free PMC article.
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
Aguilar H, Solé X, Bonifaci N, Serra-Musach J, Islam A, López-Bigas N, Méndez-Pertuz M, Beijersbergen RL, Lázaro C, Urruticoechea A, Pujana MA. Aguilar H, et al. Among authors: urruticoechea a. Oncogene. 2010 Nov 11;29(45):6071-83. doi: 10.1038/onc.2010.333. Epub 2010 Aug 16. Oncogene. 2010. PMID: 20711236
Evidence for a link between TNFRSF11A and risk of breast cancer.
Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Mariette F, Bernard L, Radice P, Kaufman B, Laitman Y, Milgrom R, Friedman E, Sáez ME, Climent F, Soler MT, Diez O, Balmaña J, Lasa A, Ramón y Cajal T, Miramar MD, de la Hoya M, Pérez-Segura P, Caldés T, Moreno V, Urruticoechea A, Brunet J, Lázaro C, Blanco I, Pujana MA, González-Suárez E. Bonifaci N, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2011 Oct;129(3):947-54. doi: 10.1007/s10549-011-1546-7. Epub 2011 May 4. Breast Cancer Res Treat. 2011. PMID: 21541702
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, Climent F, Soler MT, Muñoz P, Viñals F, Tometsko M, Branstetter D, Dougall WC, González-Suárez E. Palafox M, et al. Among authors: urruticoechea a. Cancer Res. 2012 Jun 1;72(11):2879-88. doi: 10.1158/0008-5472.CAN-12-0044. Epub 2012 Apr 10. Cancer Res. 2012. PMID: 22496457
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR. Pernas S, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8. Breast Cancer Res Treat. 2012. PMID: 22772380 Clinical Trial.
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín ÁG, López-Bonet E, Menendez JA. Martin-Castillo B, et al. Among authors: urruticoechea a. Cell Cycle. 2013 Jan 15;12(2):225-45. doi: 10.4161/cc.23274. Epub 2012 Jan 15. Cell Cycle. 2013. PMID: 23255137 Free PMC article.
Eribulin mesylate in breast cancer.
Verdaguer H, Morilla I, Urruticoechea A. Verdaguer H, et al. Among authors: urruticoechea a. Womens Health (Lond). 2013 Nov;9(6):517-26. doi: 10.2217/whe.13.61. Womens Health (Lond). 2013. PMID: 24161305 Free article.
VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA. Aguilar H, et al. Among authors: urruticoechea a. Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664. Breast Cancer Res. 2014. PMID: 24886537 Free PMC article.
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies.
Martínez-Aranda A, Hernández V, Guney E, Muixí L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, Oliva B, Moreno F, González-Suarez E, Vidal N, Andreu X, Seguí MA, Ballester R, Castella E, Sierra A. Martínez-Aranda A, et al. Among authors: urruticoechea a. Oncotarget. 2015 Dec 29;6(42):44254-73. doi: 10.18632/oncotarget.5471. Oncotarget. 2015. PMID: 26497551 Free PMC article.
79 results